Stabilization notice

Carnegie Investment Bank AB (publ) (”Carnegie”) notifies that stabilization measures have been undertaken in Calliditas Therapeutics AB (publ)’s (”Calliditas” or the “Company”) shares traded on Nasdaq Stockholm.

As announced in connection with the offering to acquire newly issued shares in the Company (the ”Offering”) and the listing of the Company’s shares on Nasdaq Stockholm, Carnegie may, acting as Sole Global Coordinator, carry out transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the market.

Stabilization transactions may be undertaken on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the first day of trading in the Company’s shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter. The Sole Global Coordinator is, however, not required to undertake any stabilization and there is no assurance that stabilization will be undertaken. Stabilization, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at levels above the price in the Offering.

The Company has granted the Sole Global Coordinator an over-allotment option, which may be utilized in whole or in part for 30 days from the first day of trading in the Company’s shares on Nasdaq Stockholm, to sell up to 2,166,666 additional shares, corresponding to up to 15 percent of the total number of shares encompassed by the Offering, at a price corresponding to the price in the Offering, i.e. SEK 45, to cover any over-allotment in connection with the Offering.

Carnegie has, in its capacity as stabilization manager, notified that stabilization measures have been undertaken, in accordance with article 5(4) in the Market Abuse Regulation 596/2014, on Nasdaq Stockholm as specified below. The contact person at Carnegie is Magnus Andersson (tel: +468- 5886 8800). 

For further information, please contact:

Renée Aguiar-Lucander, CEO at Calliditas

E-mail: renee.lucander@calliditas.com

Telephone: +46 722 52 10 06

Mikael Widell, Head of Communications at Calliditas

E-mail: mikael.widell@calliditas.com

Telephone: +46 703 11 99 60

www.calliditas.se/en/

The information in this press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons set out above, at 18.00 CEST on 12 July 2018.  

Important information

This announcement is not and does not form a part of any offer for sale of securities.

Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, the United States or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.